# A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B

> **NCT02598063** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 255 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** Adefovir dipivoxil
- **DRUG:** Lamivudine
- **DRUG:** Peginterferon alfa-2a

## Key facts

- **NCT ID:** NCT02598063
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 255 (ACTUAL)
- **Last updated:** 2016-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02598063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02598063, "A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02598063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*